Jump to ContentJump to Main Navigation
Human Genome Epidemiology, 2nd EditionBuilding the evidence for using genetic information to improve health and prevent disease$
Users without a subscription are not able to see the full content.

Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, and Julian Little

Print publication date: 2009

Print ISBN-13: 9780195398441

Published to Oxford Scholarship Online: May 2010

DOI: 10.1093/acprof:oso/9780195398441.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in OSO for personal use (for details see www.oxfordscholarship.com/page/privacy-policy).date: 25 April 2019

Cytochrome P450 testing in the treatment of depression

Cytochrome P450 testing in the treatment of depression

Chapter:
(p.597) 30 Cytochrome P450 testing in the treatment of depression
Source:
Human Genome Epidemiology, 2nd Edition
Author(s):

Iris Grossman

Mugdha Thakur

David B. Matchar

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780195398441.003.0030

This chapter reviews studies on the use of CYP450 genotyping as a guide to the management of serotonin reuptake inhibitors (SSRIs) for patients with depression. Comparison of the results of available tests for CYP450 genotype with a reference standard suggests that the analytic sensitivity and specificity of available tests are generally high, although some serious concerns remain. In the evaluation of gene deletions and duplications, assessing the magnitude of the potential error in these analytic parameters is limited by the lack of an established gold standard for gene copy number. Another concern is that few CYP450 variants were interrogated by the studies identified, which focused particularly on the more common variants in Caucasians. In depressed patients who have reached a steady-state concentration of an SSRI, the limited existing data do not demonstrate a clear correlation between CYP450 metabolizer status and (i) SSRI concentrations (an intermediate outcome), (ii) efficacy of SSRIs, or (iii) tolerability of SSRIs.

Keywords:   depression, serotonin reuptake inhibitors, CYP450 genotyping, clinical studies

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .